ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
JP
/
EN
メニューアイコン
Research
Hokuto Hospital Follow-Up of 72 miSignal Scan Users: Two Gastric Cancers Found Among the 11 Flagged People Who Chose Further Testing
2026.01.29

In about three years of routine practice at one hospital, 24 of 72 people tested were graded medium or high risk for at least one site; 11 of those 24 went on to a detailed examination, and two gastric cancers, one of them early stage, plus one case of multiple colorectal polyps were found. Whether the test missed any cancers was not measured.


TOKYO, January 29, 2026 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, reported real-world clinical follow-up data for its miSignal Scan urine microRNA test at the 54th Annual Meeting of the Japanese Society of Health Evaluation and Promotion. The work was presented as a general session abstract by researcher Shogo Baba and colleagues of the Oncology Medicine Research Institute, Next Generation Medicine Research Department at Hokuto Hospital (Social Medical Corporation Hokuto), together with Craif.

The report covers 72 people who took miSignal Scan at Hokuto Hospital between December 2022 and September 2025. Twenty-four of them were graded medium or high risk for at least one cancer site. Eleven of those 24 chose to have a detailed examination. Among those 11, gastric cancer was confirmed in two people, one of them at an early stage, and multiple colorectal polyps were found in one person.

What was reported

This was a retrospective collection of clinical records from a single hospital. It was not a prospective trial, and it was not designed to measure the test's accuracy. Craif and Hokuto Hospital reported what happened to people who took miSignal Scan during routine practice at the hospital and then went on to a detailed examination.

What the follow-up found

  • Testing period: December 2022 to September 2025, about three years.
  • People tested: 72, accounting for 74 tests.
  • Median age: 67 years.
  • Graded medium or high risk for at least one cancer site: 24 of the 72.
  • Underwent a detailed examination: 11 of those 24, all of whom chose to have one.
  • Gastric cancer confirmed: 2 of the 11, one of them at an early stage. Both had been graded medium risk for gastric cancer.
  • Multiple colorectal polyps found: 1 of the 11, in a person who had been graded medium risk for colorectal cancer. Polyps are not cancer.
  • No clear abnormality on detailed examination: the remaining 8 of the 11.

What these numbers do not show

The 48 people who were not graded medium or high risk were not followed, so these data do not show how many cancers miSignal Scan may have missed. Sensitivity, specificity and negative predictive value cannot be calculated from these data.

The 11 people who had a detailed examination chose it themselves, so they are a self-selected group within a flagged group within a 72-person series at one hospital. Outcomes for the other 13 flagged people were not reported.

Context: national screening figures

A Ministry of Health, Labour and Welfare report states that established cancer screening programs in Japan detect cancer in roughly 0.1 to 0.4 percent of people screened, with positive predictive values of roughly 2 to 6 percent, varying by cancer type and screening method. Craif states that the results suggest miSignal Scan may contribute to earlier cancer detection in routine practice as a non-invasive, simple test.

Source: Ministry of Health, Labour and Welfare, report of the Study Group on the Approach to Cancer Screening, On the Approach to Cancer Screening Programs, June 2023.

About the presentation

Title: Real-World Clinical Follow-Up of miSignal Scan, a Multi-Cancer Screening Test Using Urinary miRNA.

Presented at: the 54th Annual Meeting of the Japanese Society of Health Evaluation and Promotion, January 23 to 24, 2026, Pacifico Yokohama. Conference website: https://www.shuwa-asc.com/jhep2026/

Format: general session abstract.

About miSignal Scan

miSignal Scan extracts microRNA from urine and analyzes it with AI to assess the risk of 10 cancer types, including pancreatic cancer, by cancer type and from Stage 1. It requires only a urine sample, so testing places no physical burden on the person tested. More information is at https://misignal.jp/

Ovarian and breast cancer are assessed in women only, and prostate cancer in men only.

microRNA: very small molecules inside cells that regulate how genes work. Because the types and amounts of microRNA change in cancer cells, they can serve as clues for early detection and diagnosis of disease.

About Craif

Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.

Important information about miSignal

miSignal Scan is not a medical device. It determines risk by statistically calculating analyzed information. It does not replace a diagnosis, which is a medical act, of whether a person has cancer, and a result indicating low risk does not mean that cancer is absent or that the person will not develop cancer in the future.

Media contact

press_us@craif.com